[SCHEDULE 13G/A] Sutro Biopharma, Inc. SEC Filing
The Vanguard Group filed Amendment 9 to its Schedule 13G on Travere Therapeutics (TVTX) covering holdings as of 30 Jun 2025.
- Beneficial ownership: 5,994,283 common shares, representing 6.74 % of the outstanding class.
- Voting power: 0 shares sole, 107,100 shares shared.
- Dispositive power: 5,806,026 shares sole, 188,257 shares shared.
- Filed pursuant to Rule 13d-1(b); Vanguard is classified as an investment adviser (IA).
- Certification states shares were acquired in the ordinary course, with no intent to influence control.
The disclosure confirms Vanguard remains a passive, >5 % institutional holder in Travere, signalling continued interest without control ambitions.
The Vanguard Group ha presentato l'Emendamento 9 al suo Schedule 13G relativo a Travere Therapeutics (TVTX), con dati aggiornati al 30 giugno 2025.
- Propriet脿 effettiva: 5.994.283 azioni ordinarie, pari al 6,74% del totale delle azioni in circolazione.
- Potere di voto: 0 azioni in modo esclusivo, 107.100 azioni in condivisione.
- Potere dispositvo: 5.806.026 azioni in modo esclusivo, 188.257 azioni in condivisione.
- Depositato ai sensi della Regola 13d-1(b); Vanguard 猫 classificato come consulente d'investimento (IA).
- La certificazione dichiara che le azioni sono state acquisite nell'ordinaria gestione, senza intenzione di influenzare il controllo.
La comunicazione conferma che Vanguard rimane un investitore istituzionale passivo con oltre il 5% in Travere, indicando un interesse continuativo senza ambizioni di controllo.
The Vanguard Group present贸 la Enmienda 9 a su Schedule 13G sobre Travere Therapeutics (TVTX), con participaciones al 30 de junio de 2025.
- Propiedad beneficiaria: 5.994.283 acciones comunes, que representan el 6,74% de la clase en circulaci贸n.
- Poder de voto: 0 acciones en forma exclusiva, 107.100 acciones compartidas.
- Poder dispositvo: 5.806.026 acciones en forma exclusiva, 188.257 acciones compartidas.
- Presentado conforme a la Regla 13d-1(b); Vanguard est谩 clasificado como asesor de inversiones (IA).
- La certificaci贸n indica que las acciones se adquirieron en el curso ordinario, sin intenci贸n de influir en el control.
La divulgaci贸n confirma que Vanguard sigue siendo un tenedor institucional pasivo con m谩s del 5% en Travere, se帽alando un inter茅s continuo sin aspiraciones de control.
The Vanguard Group電� 2025雲� 6鞗� 30鞚� 旮办鞙茧 Travere Therapeutics (TVTX)鞐� 雽�頃� Schedule 13G 靾橃爼鞎� 9順鸽ゼ 鞝滌稖頄堨姷雼堧嫟.
- 鞁れ 靻岇湢甓�: 5,994,283 氤错喌欤茧, 鞝勳泊 氚滍枆 欤检嫕鞚� 6.74%鞐� 頃措嫻頃╇媹雼�.
- 鞚橁舶甓�: 雼弲 0欤�, 瓿惦彊 107,100欤� 氤挫湢.
- 觳橂秳 甓岉暅: 雼弲 5,806,026欤�, 瓿惦彊 188,257欤� 氤挫湢.
- 攴滌箼 13d-1(b)鞐� 霐半澕 鞝滌稖霅橃棃鞙茧┌, Vanguard電� 韴瀽 鞛愲靷�(IA)搿� 攵勲霅╇媹雼�.
- 鞚胳靹滌棎電� 欤检嫕鞚� 韱奠儊鞝侅澑 瓯半灅 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌, 歆�氚瓣秾 頄夓偓 鞚橂弰臧� 鞐嗢潓鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
鞚措矆 瓿奠嫓電� Vanguard臧� Travere鞐愳劀 5% 鞚挫儊 氤挫湢頃� 靾橂彊鞝� 旮瓣磤 韴瀽鞛�搿� 雮晞 鞛堨潓鞚� 頇曥澑頃橂┌, 歆�氚瓣秾鞚� 於旉惮頃橃 鞎婋姅 歆�靻嶌爜鞚� 甏�鞁潉 雮橅儉雰呺媹雼�.
The Vanguard Group a d茅pos茅 l'Amendement 9 脿 son Schedule 13G concernant Travere Therapeutics (TVTX) pour des participations au 30 juin 2025.
- Propri茅t茅 b茅n茅ficiaire : 5 994 283 actions ordinaires, repr茅sentant 6,74 % de la classe en circulation.
- Pouvoir de vote : 0 actions en propre, 107 100 actions en commun.
- Pouvoir discr茅tionnaire : 5 806 026 actions en propre, 188 257 actions en commun.
- D茅pos茅 conform茅ment 脿 la r猫gle 13d-1(b) ; Vanguard est class茅 comme conseiller en investissement (IA).
- La certification indique que les actions ont 茅t茅 acquises dans le cours normal des affaires, sans intention d'influencer le contr么le.
Cette divulgation confirme que Vanguard reste un d茅tenteur institutionnel passif de plus de 5 % dans Travere, signalant un int茅r锚t continu sans ambition de contr么le.
The Vanguard Group reichte 脛nderungsmeldung 9 zu seinem Schedule 13G bez眉glich Travere Therapeutics (TVTX) mit Stand 30. Juni 2025 ein.
- Wirtschaftliches Eigentum: 5.994.283 Stammaktien, was 6,74% der ausstehenden Aktienklasse entspricht.
- Stimmrechte: 0 Aktien allein, 107.100 Aktien gemeinsam.
- 痴别谤蹿眉驳耻苍驳蝉谤别肠丑迟别: 5.806.026 Aktien allein, 188.257 Aktien gemeinsam.
- Gem盲脽 Regel 13d-1(b) eingereicht; Vanguard wird als Investmentberater (IA) klassifiziert.
- Die Zertifizierung best盲tigt, dass die Aktien im gew枚hnlichen Gesch盲ftsverlauf erworben wurden, ohne Absicht, Kontrolle auszu眉ben.
Die Offenlegung best盲tigt, dass Vanguard weiterhin ein passiver institutioneller Anleger mit 眉ber 5% an Travere ist, was ein anhaltendes Interesse ohne Kontrollabsicht signalisiert.
- Large institutional ownership: Vanguard holds 6.74 % of TVTX, signalling continued institutional confidence and potentially enhanced share liquidity.
- None.
Insights
TL;DR Vanguard鈥檚 6.7 % stake affirms institutional support but provides no new control or strategic signal.
Vanguard retains nearly 6 M shares, solidifying its position as a top shareholder. The absence of sole voting power indicates a purely passive posture; dispositive authority remains strong, giving Vanguard flexibility to adjust exposure. While the ownership level exceeds the 5 % reporting threshold, it is not large enough to exert control, and the certification confirms no activist intent. For investors, a large passive holder can improve liquidity and enhance governance scrutiny, but it does not directly alter Travere鈥檚 strategic trajectory.
TL;DR Filing is routine; passive stake offers governance oversight but limited immediate impact.
The amendment updates share counts and complies with Section 13 reporting requirements. Vanguard鈥檚 shared voting rights (鈮�0.12 % of shares) underscore its limited influence on ballots, reducing the likelihood of proposal swings driven by this block alone. Nonetheless, Vanguard鈥檚 stewardship policies often press for ESG transparency, which could gradually shape board practices. No red flags emerge regarding attempts to influence control, so governance risk remains neutral.
The Vanguard Group ha presentato l'Emendamento 9 al suo Schedule 13G relativo a Travere Therapeutics (TVTX), con dati aggiornati al 30 giugno 2025.
- Propriet脿 effettiva: 5.994.283 azioni ordinarie, pari al 6,74% del totale delle azioni in circolazione.
- Potere di voto: 0 azioni in modo esclusivo, 107.100 azioni in condivisione.
- Potere dispositvo: 5.806.026 azioni in modo esclusivo, 188.257 azioni in condivisione.
- Depositato ai sensi della Regola 13d-1(b); Vanguard 猫 classificato come consulente d'investimento (IA).
- La certificazione dichiara che le azioni sono state acquisite nell'ordinaria gestione, senza intenzione di influenzare il controllo.
La comunicazione conferma che Vanguard rimane un investitore istituzionale passivo con oltre il 5% in Travere, indicando un interesse continuativo senza ambizioni di controllo.
The Vanguard Group present贸 la Enmienda 9 a su Schedule 13G sobre Travere Therapeutics (TVTX), con participaciones al 30 de junio de 2025.
- Propiedad beneficiaria: 5.994.283 acciones comunes, que representan el 6,74% de la clase en circulaci贸n.
- Poder de voto: 0 acciones en forma exclusiva, 107.100 acciones compartidas.
- Poder dispositvo: 5.806.026 acciones en forma exclusiva, 188.257 acciones compartidas.
- Presentado conforme a la Regla 13d-1(b); Vanguard est谩 clasificado como asesor de inversiones (IA).
- La certificaci贸n indica que las acciones se adquirieron en el curso ordinario, sin intenci贸n de influir en el control.
La divulgaci贸n confirma que Vanguard sigue siendo un tenedor institucional pasivo con m谩s del 5% en Travere, se帽alando un inter茅s continuo sin aspiraciones de control.
The Vanguard Group電� 2025雲� 6鞗� 30鞚� 旮办鞙茧 Travere Therapeutics (TVTX)鞐� 雽�頃� Schedule 13G 靾橃爼鞎� 9順鸽ゼ 鞝滌稖頄堨姷雼堧嫟.
- 鞁れ 靻岇湢甓�: 5,994,283 氤错喌欤茧, 鞝勳泊 氚滍枆 欤检嫕鞚� 6.74%鞐� 頃措嫻頃╇媹雼�.
- 鞚橁舶甓�: 雼弲 0欤�, 瓿惦彊 107,100欤� 氤挫湢.
- 觳橂秳 甓岉暅: 雼弲 5,806,026欤�, 瓿惦彊 188,257欤� 氤挫湢.
- 攴滌箼 13d-1(b)鞐� 霐半澕 鞝滌稖霅橃棃鞙茧┌, Vanguard電� 韴瀽 鞛愲靷�(IA)搿� 攵勲霅╇媹雼�.
- 鞚胳靹滌棎電� 欤检嫕鞚� 韱奠儊鞝侅澑 瓯半灅 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌, 歆�氚瓣秾 頄夓偓 鞚橂弰臧� 鞐嗢潓鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟.
鞚措矆 瓿奠嫓電� Vanguard臧� Travere鞐愳劀 5% 鞚挫儊 氤挫湢頃� 靾橂彊鞝� 旮瓣磤 韴瀽鞛�搿� 雮晞 鞛堨潓鞚� 頇曥澑頃橂┌, 歆�氚瓣秾鞚� 於旉惮頃橃 鞎婋姅 歆�靻嶌爜鞚� 甏�鞁潉 雮橅儉雰呺媹雼�.
The Vanguard Group a d茅pos茅 l'Amendement 9 脿 son Schedule 13G concernant Travere Therapeutics (TVTX) pour des participations au 30 juin 2025.
- Propri茅t茅 b茅n茅ficiaire : 5 994 283 actions ordinaires, repr茅sentant 6,74 % de la classe en circulation.
- Pouvoir de vote : 0 actions en propre, 107 100 actions en commun.
- Pouvoir discr茅tionnaire : 5 806 026 actions en propre, 188 257 actions en commun.
- D茅pos茅 conform茅ment 脿 la r猫gle 13d-1(b) ; Vanguard est class茅 comme conseiller en investissement (IA).
- La certification indique que les actions ont 茅t茅 acquises dans le cours normal des affaires, sans intention d'influencer le contr么le.
Cette divulgation confirme que Vanguard reste un d茅tenteur institutionnel passif de plus de 5 % dans Travere, signalant un int茅r锚t continu sans ambition de contr么le.
The Vanguard Group reichte 脛nderungsmeldung 9 zu seinem Schedule 13G bez眉glich Travere Therapeutics (TVTX) mit Stand 30. Juni 2025 ein.
- Wirtschaftliches Eigentum: 5.994.283 Stammaktien, was 6,74% der ausstehenden Aktienklasse entspricht.
- Stimmrechte: 0 Aktien allein, 107.100 Aktien gemeinsam.
- 痴别谤蹿眉驳耻苍驳蝉谤别肠丑迟别: 5.806.026 Aktien allein, 188.257 Aktien gemeinsam.
- Gem盲脽 Regel 13d-1(b) eingereicht; Vanguard wird als Investmentberater (IA) klassifiziert.
- Die Zertifizierung best盲tigt, dass die Aktien im gew枚hnlichen Gesch盲ftsverlauf erworben wurden, ohne Absicht, Kontrolle auszu眉ben.
Die Offenlegung best盲tigt, dass Vanguard weiterhin ein passiver institutioneller Anleger mit 眉ber 5% an Travere ist, was ein anhaltendes Interesse ohne Kontrollabsicht signalisiert.
FAQ
How many Travere Therapeutics (TVTX) shares does Vanguard now own?
What percentage of Travere鈥檚 outstanding shares does this represent?
Does Vanguard have voting control over Travere?
Is Vanguard acting as an activist investor in this filing?
Why did Vanguard file Schedule 13G rather than 13D?
